(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer.
The results, which were published online June 5, 2014 in the journal Gynecologic Oncology, showed that biweekly gemcitabine, carboplatin, and bevacizumab led to better response rates and progression free survival than with gemcitabine carboplatin alone.
Furthermore, the experimental regimen was well tolerated, with an acceptable incidence of neutropenia and no reported bowel perforations.
